Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 44Hodgkin Disease 8Neoplasm Metastasis 6Neoplasms 5Leiomyosarcoma 5Skin Neoplasms 4Lymphoma 4Uveal Melanoma 3Sarcoma 3Hematologic Diseases 2Solid Tumor 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Liposarcoma 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoma 1Breast Neoplasms 1Advanced Melanoma 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Dacarbazine × Clear all
NCT02288897 2022-01-19

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Provectus Pharmaceuticals

Phase 3 Terminated
20 enrolled 13 charts
Dermatologic

Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡